Naslov
V617F mutation in JAK2 is associated idiopathic myelofibrosis

Autori
Campbell, Peter ; Griesshammer, Martin ; Dohner, Konstanze ; Dohner, Hartmut ; Kušec, Rajko ; Hasselbalch, Hans ; Larsen, Thomas ; Pallisgaard, Niels ; Giraudier, Stephane ; Le Bousse-Kerdiles, Marie Caroline ; Desterke, Christophe ; Guerton, Bernadette ; Dupriez, Brigitte ; Bordessoule, Dominique ; Fenaux, Pierre ; Kiladjian, Viallard Jean-Jacques F. ; Briere, Jean ; Harrison, Claire N. ; Green, Anthony A. ; Reilly, John T.

Izvornik
Blood (0006-4971) 107 (2006), 5; 2098-2100

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
V617F Jak2; myelofibrosis; prognosis; chronic myeloproliferation

Sažetak
Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive PCR-based methods, we genotyped 152 patients with idiopathic myelofibrosis in order to establish whether there were differences in presentation and outcome between those with and those without the mutation. V617F-positive patients had higher neutrophil and white cell counts (p=0.02) than V617F-negative patients, but other diagnostic features were comparable between the two groups. V617F-positive patients were less likely to require blood transfusion during follow-up (p=0.03). Despite this, V617F-positive patients had poorer overall survival, even after correction for confounding factors (p=0.01).

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA